OR WAIT null SECS
October 06, 2022
The UK’s MHRA has approved Colonis’ melatonin oral solution for sleep onset insomnia in children and adolescents with ADHD.
H.I.G. Capital’s portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals.
Klucel xtend HPC is the latest addition to the company’s Klucel product line and further expands their controlled-release portfolio.
October 04, 2022
FDA has granted Fast Track designation for CUE-101, a treatment of recurrent/metastatic head and neck squamous cell carcinoma.
Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.
October 02, 2022
Pharmaceutical Technology Europe pays tribute to the role Her Majesty Queen Elizabeth II had in promoting innovation within life sciences.
September 30, 2022
Novo Nordisk will pay up to $700 million for the exclusive rights to develop and commercialize candidates from Ventus Therapeutics NLRP3 inhibitor portfolio.
FDA has approved Relyrio as a once-to-twice daily treatment for patients with ALS.
Citius and the University of Pittsburgh will investigate I/ONTAK in combination with pembrolizumab for treatment of recurrent or metastatic solid tumors.
Forge Biologics will offer three grades of plasmid manufacturing services at its Columbus, Ohio, location.